Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based studyCoronaVac, BNT162b2, ChAdOx1 COVID-19 백신 및 단일 추가 접종 후 SARS-CoV-2 anti-spike 수용체 결합 도메인 IgG 항체 반응의 비교: 전향적, 종단적 인구 기반 연구Article Published on 2022-04-012022-09-12 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI addition age Anti-spike Anti-spike RBD IgG antibody antibody level Antibody Response Antibody titre antibody titres baseline characteristics blood sample BNT162b2 boost booster booster dose ChAdOx1 ChAdOx1 vaccines collected concentrations CoronaVac COVID-19 pandemic COVID-19 vaccines Cyprus distribution dose evaluated Follow-up General population geometric group health-care help high-risk population highest IgG IgG antibody individual inoculated Laboratory Longitudinal data Male sex of BNT162b2 offered Older Older age participant RBD Reactions Receptor binding domain recruited regimen repeated measure Responder response SARS-CoV-2 second dose significantly significantly increased titre vaccination Vaccination strategies Vaccine was done [DOI] 10.1016/S2666-5247(21)00305-0 PMC 바로가기 [Article Type] Article
The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individualsSARS-CoV-2의 E484K 돌연변이가 BNT162b2 백신을 접종한 개인의 항체 중화 활성에 미치는 영향Article Published on 2022-03-182022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibody Antibody titer Antibody titers Beta Beta variant BNT162b2 BNT162b2 vaccine caused collected E484K E484K mutation Efficacy FIVE geometric geometric mean healthy humoral Humoral immunity Japanese Lineage N501Y mutation Neutralization antibody neutralization titer Neutralizing activity participant receiving reduced responsible SARS-CoV-2 SARS-CoV-2 variants second dose Serum Neutralization serum sample serum samples strain the SARS-CoV-2 thought vaccinated individual Vaccine vaccine efficacy variant was measured weakened were measured [DOI] 10.1016/j.vaccine.2022.02.047 PMC 바로가기 [Article Type] Article
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity2개의 재조합 이량체 RBD COVID-19 백신 후보에 대한 무작위 이중 맹검 1상 임상 시험: 안전성, 반응성 및 면역원성Clinical Trial Published on 2022-03-182022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] adjuvants adverse event anti-RBD Anti-RBD IgG association baseline candidate clinical trial Coronavirus infection COVID-19 COVID-19 vaccine COVID-19 vaccines dimeric dose doses double-blind ELISA evaluated geometric Heterologous highest homologous or heterologous homologous schedule Humoral response immunization schedule immunogenic Immunopotentiator In-vitro intensity Interaction Local Mild MOST neutralization Neutralizing Neutralizing antibodies neutralizing antibody outer membrane Panel performed Phase I Primary outcome Randomized randomly divided RBD reactogenicity receive reported Safe Safety SARS-CoV-2 second dose secondary outcome Seroconversion significantly Spike protein subject the SARS-CoV-2 three group titre toxicology two groups vaccination vaccine candidate vaccine immunogenicity Vaccines Vesicle Volunteer were used [DOI] 10.1016/j.vaccine.2022.02.029 PMC 바로가기 [Article Type] Clinical Trial
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report건강한 일본 성인을 대상으로 한 코로나19 백신 mRNA-1273의 1/2상 무작위 위약 대조 연구: 중간 보고서Clinical Trial Published on 2022-03-182022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered adverse event AEs age AMED anti-SARS-CoV-2 immune response antibody ARMS baseline company conducted coronavirus COVID-19 COVID-19 vaccine mRNA-1273 demonstrated development dose ENCODE enrolled fatigue geometric healthy immune response immunogenicity Injection-site pain Interim report Intramuscular injection Japan Japanese Limited mRNA vaccine mRNA-1273 myalgia NAb neutralising antibody occurred outcome participant Participants pharmaceutical Placebo placebo-controlled study placebo-controlled trial randomised receive reported Safety safety profile SARS-CoV-2 SARS-COV-2 infection secondary outcome Spike protein stratified Takeda vaccination Vaccine [DOI] 10.1016/j.vaccine.2022.02.030 PMC 바로가기 [Article Type] Clinical Trial
Deep learning guided optimization of human antibody against SARS-CoV-2 variants with broad neutralization광범위한 중화를 통해 SARS-CoV-2 변이체에 대한 인간 항체의 딥 러닝 유도 최적화Article Published on 2022-03-152022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] MERS, SARS, 변종, 진단, [키워드] antibodies antibody approach broadly neutralizing antibodies catch CDRs complementarity-determining region complementarity-determining regions Computational biology deep deep learning evade Evolution geometric geometric neural networks. immune response include introduced lead Mutation neutralization neutralize Neutralizing Neutralizing antibodies Protein SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants selection pressure Spike protein the Spike Transmissibility Vaccine variant variants virus virus variant [DOI] 10.1073/pnas.2122954119 PMC 바로가기 [Article Type] Article
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansSARS-CoV-2 단일클론항체 조합인 AZD7442는 인간이 아닌 영장류를 보호하고 인간에서 반감기가 연장됩니다.Article Published on 2022-03-092022-09-11 Journal: Science Translational Medicine [Category] MERS, SARS, 변종, 비임상, 진단, 치료기술, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration angiotensin angiotensin-converting enzyme 2 Angiotensin-converting enzyme 2 receptor antibody benefit binding cell entry cilgavimab Combination Concentration convalescent serum coronavirus coronavirus disease Coronavirus disease 2019 Course COVID-19 death Epitopes extrapolation fold functions geometric geometric mean greater half-live healthy Human individual Infection Initially Intramuscular injection lung mAb mAbs monoclonal antibodies monoclonal antibody combination nasal mucosa neutralize Neutralizing titer nonoverlapping epitope nonoverlapping epitopes participant Phase 1 phase 1 study Prevent prevented Prophylactic Protective provided receptor Receptor binding domain reduce remained respiratory risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant serum severe acute respiratory syndrome Coronavirus severe disease Spike protein Spike protein receptor binding domain tested the spike protein therapeutic Tixagevimab treat Treatment Vaccines Viral viral spike protein virus virus clearance [DOI] 10.1126/scitranslmed.abl8124 PMC 바로가기 [Article Type] Article
Fulminant and Non-fulminant Clinical COVID-19 Myocarditis in the New York City Area in 2020Observational Study Published on 2022-03-082022-10-05 Journal: Annals of Global Health [Category] 임상, [키워드] Area Atrial fibrillation Characteristics clinical Clinical course clinically complication of COVID-19 Coronary artery disease COVID-19 cross-sectional D-dimer defined Diagnosis echocardiographic Elevation Exploratory analysis ferritin fulminant generate geometric hypothese increasingly Inflammatory marker Isolation Laboratory Laboratory testing limitations Logistic regression MRI myocarditis New York City offer Patient patients precautions presenting symptoms required resource severity severity of COVID-19 significantly higher stratified Student T-test supplemental oxygen systemic inflammation to define ventricular while [DOI] 10.5334/aogh.3583 PMC 바로가기 [Article Type] Observational Study
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants다양한 SARS-CoV-2 변이체에 대한 삼중 백신 접종자의 기억 B 세포 레퍼토리Article Published on 2022-03-012022-09-11 Journal: Nature [Category] MERS, SARS, 변종, 진단, [키워드] active against antibody Antibody titre B.1.1.529 B.1.351 Beta binding class complex defined determinant dose Effectiveness epitope Epitopes examined FIVE geometric geometric mean greater human monoclonal antibodies Human monoclonal antibody immunization inactivated individual Infection Local memory B cell memory B cells mice monoclonal antibodies mutated neutralization neutralize neutralized Neutralizing Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibody omicron Protective raising Receptor-binding domain recipient recipients regimen sarbecovirus SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant sera seroconversion rate seroconversion rates Spike protein Structure subset target the receptor-binding domain therapy Treatment Vaccine vaccine doses vaccinee vaccinees variants of concern virus [DOI] 10.1038/s41586-022-04466-x PMC 바로가기 [Article Type] Article
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong홍콩 백신 중 우려되는 SARS-CoV-2 변종에 대한 면역 반응 약화Article Published on 2022-03-012022-09-11 Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단, 치료기술, 치료법, [키워드] Against AIDS B.1.1.529 B.1.617.2 BNT162b2 Breakthrough infection CD4 CD8 Cell Cellular immune response China Commission CoronaVac Council Delta Detection limit development dose dropped education Faculty of Medicine Frequency Friend friends geometric geometric mean higher risk Hong Kong Hope humoral immune response IFN-γ immune immune response immunogenicity Inactivated vaccine induce Innovation investigated matching median memory T memory T cell mRNA mRNA vaccine NAb nAb response NAbs neutralizing antibody nucleocapsid nucleocapsid protein omicron pandemic Program reactive reduced response rates responses SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants Science Shenzhen significantly significantly lower Standard subset supported T cell T cell response T cells technology vaccination Vaccinations Vaccine Vaccine-induced immunity vaccinee vaccinees VoC VOCs Wellcome Trust [DOI] 10.1016/j.ebiom.2022.103904 PMC 바로가기 [Article Type] Article
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종Clinical Trial Published on 2022-02-052022-08-13 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술, [키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine [DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial